Schonfeld Strategic Advisors LLC Kura Oncology, Inc. Transaction History

Schonfeld Strategic Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$10.71 - $14.6 $581,049 - $792,093	54,253 New	54,253 $663,000
Q4 2021 Feb 14, 2022	SELL	$12.22 - $19.57 $556,010 - $890,435	-45,500 Closed	0 $0
Q3 2021 Nov 16, 2021	SELL	$15.42 - $21.72 $670,770 - $944,820	-43,500 Reduced 48.88%	45,500 $852,000
Q2 2021 Aug 16, 2021	BUY	$20.85 - $29.88 $89,613 - $128,424	4,298 Added 5.07%	89,000 $1.86 Million
Q1 2021 May 17, 2021	BUY	$24.75 - $39.14 $1.6 Million - $2.52 Million	64,464 Added 318.53%	84,702 $2.4 Million
Q4 2020 Feb 16, 2021	SELL	$29.0 - $41.62 $187,891 - $269,655	-6,479 Reduced 24.25%	20,238 $660,000
Q3 2020 Nov 16, 2020	BUY	$16.3 - $30.64 $435,487 - $818,608	26,717 New	26,717 $1,000
Q4 2018 Feb 14, 2019	SELL	$10.6 - $17.49 $2.82 Million - $4.66 Million	-266,300 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$16.65 - $21.85 $3.04 Million - $3.99 Million	182,400 Added 217.4%	266,300 $4.66 Million
Q2 2018 Aug 14, 2018	SELL	$14.8 - $18.8 $24,804 - $31,508	-1,676 Reduced 1.96%	83,900 $1.53 Million
Q1 2018 May 15, 2018	BUY	$14.5 - $23.4 $1.24 Million - $2 Million	85,576 New	85,576 $1.61 Million

185

81.8M

42.1K

34K

Ticker KURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,893,000
Market Cap $598M
Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.